BioSpace News Archive

Apnimed, today announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182.

Vesigen Therapeutics Presents at 3rd Exosome-Based Therapeutic Development Summit: Expanding the Therapeutic Boundaries of Exosomes

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada has approved the companies’ Clinical Trial Application (CTA) for VCTX210,

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) published their summary opinion in support of approval of SIGA’s Marketing Authorisation Application (MAA) for oral tecovirimat.

The new name signifies its expanding focus on collaborative clinical research and broader diagnostic capabilities

PacBio (Nasdaq: PACB), today announced the launch of the HiFiViral SARS-CoV-2 Kit – a fully kitted end-to-end solution for COVID-19 surveillance, which public health laboratories can use to identify new SARS-CoV-2 variants and detect all variants circulating within a population.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today that it has partnered with Arizona State University to develop a COVID-19 “Correlate of Protection” using AXIM’s rapid neutralizing antibody test.

Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced its participation in the upcoming investor conferences.

VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal.

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the start of a clinical study program focused on optimizing and expanding the market positioning of its in-licensed FDA-approved prescription drug Ameluz® for photodynamic therapy in the United States.